Fight Fatigue for Kidney Failure
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method to ease fatigue in adults with severe kidney disease undergoing regular dialysis. It combines muscle relaxation exercises and walking to determine if these activities can reduce tiredness. Participants will be divided into two groups: one will try the new program called "Fight Fatigue," while the other will receive education about kidney disease. Candidates may qualify if they have been on dialysis for at least three months, often feel tired, and can walk a block. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could enhance the quality of life for dialysis patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this intervention is safe for adults with end-stage kidney disease?
Research has shown that exercise and relaxation techniques are generally safe for people on dialysis. Studies of similar programs have found that participants handle them well. For instance, research on exercise for dialysis patients showed it improved health without causing major side effects. Progressive muscle relaxation, included in this trial, has been safely used in other kidney disease groups. Another study found that combining relaxation with mindfulness did not lead to serious issues. These findings suggest that the treatment in this trial is likely safe for participants.12345
Why are researchers excited about this trial?
Researchers are excited about the Fight Fatigue program for kidney failure because it combines progressive muscle relaxation with increasing physical activity, specifically through walking. Unlike standard treatments that focus on medication or dialysis to manage symptoms, this approach emphasizes lifestyle changes that can empower patients to take an active role in their well-being. The intervention also includes education and supportive text messages, offering a holistic strategy that addresses both physical and mental health aspects of fatigue. This innovative method could provide a non-invasive, sustainable way to manage fatigue, potentially improving patients' quality of life significantly.
What evidence suggests that this intervention is effective for reducing fatigue in end-stage kidney disease?
This trial will compare a combined progressive muscle relaxation and walking intervention with an attention control group. Studies have shown that progressive muscle relaxation can reduce tiredness in people on dialysis. This method, combined with walking, may slow or prevent the worsening of kidney disease. Early findings suggest that this type of exercise could effectively combat fatigue. Research also shows that patients and caregivers consider exercise important for improving well-being during kidney treatments. While more information is needed, these early results suggest a positive effect on energy levels.12678
Are You a Good Fit for This Trial?
This trial is for adults with end-stage kidney disease (ESKD) who feel very tired, can walk at least one block, have a cell phone to receive texts, and speak English. They should be on hemodialysis for 3+ months but not if they're unable to follow the study procedures.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo a 12-week intervention involving progressive muscle relaxation and walking, with education/training and text message support
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Fight Fatigue
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Illinois at Chicago
Lead Sponsor
National Center for Complementary and Integrative Health (NCCIH)
Collaborator